Lycia Therapeutics (NASDAQ:LYCA) Stock Rated Buy in New Coverage at TD Cowen

TD Cowen assumed coverage on shares of Lycia Therapeutics (NASDAQ:LYCA – Free Report) in a research report report published on Tuesday morning, Marketbeat Ratings reports. The firm issued a buy rating on the stock.

Other analysts have also recently issued research reports about the company. Evercore began coverage on Lycia Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $43.00 price target for the company. Guggenheim started coverage on shares of Lycia Therapeutics in a research note on Tuesday. They set a “buy” rating and a $75.00 price objective for the company. Wall Street Zen upgraded shares of Lycia Therapeutics to a “hold” rating in a report on Saturday, October 31st. Finally, Jefferies Financial Group began coverage on shares of Lycia Therapeutics in a report on Tuesday. They set a “buy” rating and a $50.00 price objective on the stock. Five research analysts have rated the stock with a Buy rating. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $54.00.

Check Out Our Latest Analysis on Lycia Therapeutics

Lycia Therapeutics Trading Up 1.3%

NASDAQ LYCA opened at $31.77 on Tuesday. Lycia Therapeutics has a twelve month low of $22.19 and a twelve month high of $36.49.

Insider Buying and Selling at Lycia Therapeutics

In related news, major shareholder Venrock Healthcare Capital Par purchased 1,952,705 shares of the firm’s stock in a transaction on Monday, October 26th. The shares were bought at an average price of $18.04 per share, for a total transaction of $35,226,798.20. Following the acquisition, the insider directly owned 6,785,437 shares in the company, valued at $122,409,283.48. This trade represents a 40.41% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at this link. In the last quarter, insiders have acquired 2,078,749 shares of company stock valued at $38,526,342.

About Lycia Therapeutics

(Get Free Report)

Lycia Therapeutics is a biotechnology company developing medicines that use its lysosomal targeting chimera (LYTAC) platform to direct disease-related proteins for breakdown inside cells. The approach is designed to address extracellular and cell-surface proteins that may be difficult to target with conventional drug therapies. The company’s work is research and development-focused; it does not have marketed products. Its programs aim to apply targeted protein degradation to conditions including cancer and inflammatory diseases.

Further Reading

Analyst Recommendations for Lycia Therapeutics (NASDAQ:LYCA)

Receive News & Ratings for Lycia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lycia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.